Q-omics provides the consensus-scored MAP2K2 profile across patient tissues and cancer cell-line models. MAP2K2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MAP2K2 is differentially expressed in 14, with the highest sampling consensus in LIHC. Additionally, MAP2K2 protein abundance shows 19,682 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, LIHC, and PDAC as cancer lineages where MAP2K2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAP2K2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAP2K2 survival associations across molecular data types. MAP2K2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAP2K2 RNA expression–survival associations across cancer types. High MAP2K2 expression shows unfavorable associations in ACC, KICH and LIHC, but favorable associations in HNSC, UCEC and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MAP2K2 RNA expression.
This table summarizes MAP2K2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MAP2K2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAP2K2 shows higher tumor expression in LIHC, KIRC, LUSC, HNSC, CHOL and STAD. The LIHC box plot shows higher MAP2K2 RNA expression in tumor versus normal tissue (log2 FC = +1.576, t-test p < 0.001).
This table shows molecular features associated with MAP2K2 in patient tissues and cancer cell lines. In patient samples, MAP2K2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, MAP2K2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and SKIN.
